Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review
- 915 Downloads
The purpose of this study was to firstly present the maiden case of tamoxifen-induced acute cutaneous lupus erythematosus (ACLE), and secondly, to broaden the discussion into a systematic review of the various tamoxifen-related skin changes documented in patients with breast cancer. We searched PubMed, Cochrane, Embase, CancerLit, Scopus, Web of Science, and Google Scholar databases using keywords to identify reported cases of tamoxifen-related cutaneous adverse events. Outcomes captured included type of cutaneous reaction, time to adverse event, pathologic mechanism, and possible treatment. From 17 clinical studies identified, over ten distinct types of adverse reactions of the skin were itemized. The character of these cutaneous events ranged from the relatively common hot flashes to the rare, but potentially life-threatening, Steven Johnson syndrome. Overall, tamoxifen is generally a well-tolerated hormone therapy with decades of supporting safety data. Based on current medical literature, we present the first case of tamoxifen-induced ACLE. Our clinical experience of managing this case revealed that despite its broad use and the frequency of associated skin reactions, there is a lack of concise information detailing the cutaneous adverse events associated with tamoxifen. The absence of summarized information concerning tamoxifen-related skin changes prompted us to perform a review herein.
KeywordsBreast cancer Drug-induced lupus Hypersensitivity Rash Skin Tamoxifen
Authors wish to thank the Librarians at the Ottawa Hospital for their generous support towards rendering the availability of original articles. Specific gratitude extended to Ms. Johanne Gohier in this regard.
Conflicts of interest
The authors indicate no conflicts of interest.
- 1.Jordan VC (1997) Tamoxifen treatment for breast cancer: concept to gold standard. Oncology (Williston Park, NY) 11(2 Suppl 1):7–13Google Scholar
- 2.Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. doi: 10.1200/jco.2009.26.3756 PubMedCrossRefGoogle Scholar
- 3.Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(23):2942–2962. doi: 10.1200/jco.2013.49.3122 PubMedCrossRefGoogle Scholar
- 4.Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484. doi: 10.1056/nejm198902233200802 PubMedCrossRefGoogle Scholar
- 5.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. doi: 10.1016/s0140-6736(12)61963-1 PubMedCrossRefPubMedCentralGoogle Scholar
- 6.Craig JV (1994) The development of tamoxifen for breast cancer therapy. In: Craig JV (ed) Long-term tamoxifen treatment for breast cancer. Wisconsin Press, Wisconsin, pp 4–26Google Scholar
- 11.Ingle JN, Green SJ, Ahmann DL, Edmonson JH, Nichols WC, Frytak S, Rubin J (1982) Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 42(8 Suppl):3461s–3467sPubMedGoogle Scholar
- 15.Kim SW, Yoon HS (2009) Tamoxifen-induced melasma in a postmenopausal woman. J Eur Acad Dermatol Venereol 23(10):1199–1200Google Scholar
- 23.Drago F, Arditi M, Rebora A (1990) Tamoxifen and purpuric vasculitis. Ann Intern Med 112(12):965–966Google Scholar
- 24.Baptista MZ, Prieto VG, Chon S, Hortobagyi GN, Esteva FJ (2006) Tamoxifen-related vasculitis. J Clin Oncol 24(21):3504–3505Google Scholar
- 25.Candelaria M, Hurtado-Monroy R, Vargas-Viveros P, Carrillo-Muñnoz S, Duenas-Gonzalez A (2007) Tamoxifen-associated vasculitis in a breast cancer patient. World J Surg Oncol 5:9Google Scholar
- 26.Betto P, Gennari E, Germi L, Bonoldi E, Scalco G, Tosti A (2008) Tamoxifen and purpuric vasculitis: a case report. J Eur Acad Dermatol Venereol 22(6):762–763Google Scholar